ArticleBMC cancer2005
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.
Article in BMC cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.Frontiers in oncology · 2020Pooled it
- Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.PloS one · 2012Trial
- [Peritoneal carcinomatosis secondary to CUP syndrome : Diagnosis and indications for multimodal treatment].Radiologie (Heidelberg, Germany) · 2023Review
- Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary withFrontiers in pharmacology · 2023Article
- Study of angiogenesis in invasive breast carcinoma by morphometry and immunohistochemistry.Medical journal, Armed Forces India · 2022Article
- A Systematic Review of Cancer of Unknown Primary in the Head and Neck Region.Cancer management and research · 2021Review
- Progress in refining the clinical management of cancer of unknown primary in the molecular era.Nature reviews. Clinical oncology · 2020Review
- Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?British journal of cancer · 2020Review
- Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?Journal of Cancer · 2020Review
- "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?Frontiers in oncology · 2019Review
- Article
- Toward angiogenesis of implanted bio-artificial liver using scaffolds with type I collagen and adipose tissue-derived stem cells.Korean journal of hepato-biliary-pancreatic surgery · 2015Article
- Article
- Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site.BMC cancer · 2014Article
- Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density.Oncology letters · 2014Article
- Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.BMC cancer · 2013Article
- Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.Clinical & experimental metastasis · 2012Article
- Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells.Molecules (Basel, Switzerland) · 2012Article
- Angiogenesis in unknown primary tumors.Clinical and experimental medicine · 2012Article
- Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer.Journal of experimental & clinical cancer research : CR · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets.
methodsParaffin embedded archival material from 81 patients diagnosed with CUP was used. Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell carcinoma (5%). The tissue expression of CD34, VEGF and TSP-1 was assessed immunohistochemically by use of specific monoclonal antibodies and was analyzed against clinicopathological data.
resultsVEGF expression was detected in all cases and was strong in 83%. Stromal expression of TSP-1 was seen in 80% of cases and was strong in 20%. The expression of both proteins was not associated with any clinical or pathological parameters. Tumor MVD was higher in tumors classified as unfavorable compared to more favorable and was positively associated with VEGF and negatively with TSP-1.
conclusionAngiogenesis is very active and expression of VEGF is almost universal in cancers of unknown primary. These findings support the clinical investigation of VEGF targeted therapy in this clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.